Drug-eluting Balloon in Bifurcations Trial

Inclusion Criteria: * Stable angina pectoris (CCS class 1,2,3,4) or unstable angina and documented ischemia or silent ischemia * Patients eligible for coronary revascularisation * The target bifurcation lesion has a major native coronary artery (\>2.5mm) with a stenosis \> 50% (on visual assessment) located at a side branch (\>2mm) * Patient must be acceptable for CABG * De novo lesion * The main vessel lesion can be covered by one stent (up to 32mm) * Only one target lesion can be included in the study: other lesions in different vessels are successfully treated before the treatment of the target lesion (residual stenosis \<30%, stent well deployed, no residual dissection, normal TIMI flow, no chest pain, ECG unchanged compared to pre-procedural ECG) * Signed patients informed consent Exclusion Criteria: * Patient unable to give informed consent * Patients with a previous PCI in the target vessel * Patients with in stent restenosis of target lesion * Left ventricular ejection fraction more than 30% * Patients with left main disease * Severe calcifications with an undilatable lesion during balloon predilatation * History of bleeding diathesis * Untreated significant lesion greater than 50% diameter stenosis remaining proximal or distal to the target intervention. * Patient has suffered a stroke or TIA within the past 3 months * Life expectancy \< 1 year * Any major surgery planned or required during the next 6 months * Acute Myocardial Infarction * Only one target lesion can be included in the study * Allergy to contrast and/or required anti-platelet medication * Patients unwilling to return for follow-up at 6 months